TDOC:NYSETeladoc Health, Inc. Analysis
Data as of 2026-09-01 - not real-time
$6.34
Latest Price
9/10Risk
Risk Level: High
Executive Summary
The moving-average structure behind Teladoc Health, Inc. is neutral at $6.34, with no clear ordering between short and long averages. It has lost 34.3% over the past 30 days. With RSI at 38.2 the momentum picture is approaching oversold, alongside a bullish MACD signal. The recent range runs from support at $6.12 up to resistance at $7.24.
The company is not currently profitable on a trailing basis, so earnings multiples offer no valuation support. Consensus targets land 20.9% above where the shares trade now. Revenue is contracting at 4.0% on a -7.1% profit margin.
Risk comes out at 9 of a possible 10, a high reading. With 30-day volatility of 107.5%, a beta of 1.22 and a maximum drawdown of 52.7%, position sizing matters more than entry timing here. The wider market backdrop reads extreme greed at 93 on the fear-greed composite.
Across every horizon the signals point the same way: hold, at a conviction of 1 out of 10.
The company is not currently profitable on a trailing basis, so earnings multiples offer no valuation support. Consensus targets land 20.9% above where the shares trade now. Revenue is contracting at 4.0% on a -7.1% profit margin.
Risk comes out at 9 of a possible 10, a high reading. With 30-day volatility of 107.5%, a beta of 1.22 and a maximum drawdown of 52.7%, position sizing matters more than entry timing here. The wider market backdrop reads extreme greed at 93 on the fear-greed composite.
Across every horizon the signals point the same way: hold, at a conviction of 1 out of 10.
Top Market Events
BetterHelp's cash-pay revenue collapsed 20% as Teladoc missed its revenue target and slashed full-year guidance,...Digital medical services platform Teladoc Health NYSE:TDOC in Q2 CY2026, with sales falling 4% year on year to $606.NEW YORK, July 29, 2026 GLOBE NEWSWIRE -- Teladoc Health, Inc.
Market Outlook
Short Term
< 1 yearNeutral
Model confidence: 1/10
Key Factors
- Trading below the 200-day average of 6.70
- MACD momentum is positive
- 30-day price change of -34.3%
Medium Term
1–3 yearsNeutral
Model confidence: 1/10
Key Factors
- Trading below the 200-day average of 6.70
- Analyst targets imply +20.9% versus the current price
- 30-day volatility of 107.5%
Long Term
> 3 yearsNeutral
Model confidence: 1/10
Key Factors
- Negative profit margin of -7.1%
- Analyst targets imply +20.9% versus the current price
- Negative return on equity of -13.0%
Key Metrics & Analysis
Financial Health
Revenue Growth-4.00%
Profit Margin-7.13%
P/E Ratio-8.1
ROE-12.98%
ROA-3.22%
Debt/Equity79.09
P/B Ratio0.9
Op. Cash Flow$261.2M
Free Cash Flow$191.0M
Industry P/E30.4
Technical Analysis
TrendNeutral
RSI38.2
Support$6.12
Resistance$7.24
MA 20$6.61
MA 50$7.88
MA 200$6.70
MACDBullish
VolumeDecreasing
Fear & Greed Index93.3
Valuation
Fair Value$11.94
Target Price$7.67
Upside/Downside20.93%
GradeUndervalued
TypeBlend
Risk Assessment
Beta1.22
Volatility107.51%
Sector RiskMedium
Reg. RiskHigh
Geo RiskLow
Currency RiskLow
Liquidity RiskLow
Similar Tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.